User login
The burdens that monthly or every-other-month injections in the eye impose on patients with retinal diseases are well-known to be barriers to care for many people with these conditions. Making treatment less onerous has driven research into new treatments since the US Food and Drug Administration (FDA) approved ranibizumab (Lucentis) in 2006 as the first anti–vascular endothelial growth factor (VEGF) for the treatment of age-related macular degeneration (AMD) and other retinal diseases.
Those Several of those investigational therapies are poised to hit meaningful milestones in 2024.
Regular Eye Injections: How We Got Here
Ranibizumab originally received approval as a monthly injection. Since then, protocols have evolved to space those injections out to every other month in some, but not all, patients.
New drugs have emerged that require less frequent injections. In 2022, the anti-VEGF and angiopoietin-2 inhibitor faricimab (Vabysmo) was approved for dosing up to every 4 months. Last year, the FDA approved a high-dose formulation of the anti-VEGF treatment aflibercept 8 mg (Eylea HD) to be given every 2-4 months, as well.
But even these treatments require patients going to the office at least three or four times a year for injections, Reginald Sanders, MD, president of the American Society of Retina Specialist, Chicago, and a retina specialist in Washington, DC, told this news organization. “Now with injections, you have the anxiety of getting the injections, you have the inconvenience of coming in on a regular basis to get the injections, and you have mild discomfort — but you don’t go blind,” Dr. Sanders said.
Studies have shown patients with AMD or diabetic macular edema are better off getting more frequent injections, but still drug developers are seeking the holy grail of fewer injections. “How do we make these treatments last longer?” Dr. Sanders said. “Durability has become the catchword in our field. Instead of lasting a month or 2, can it last 3 months? Can it last 6 months? Or even a year? Can you get one injection and be done with it?”
Or, no injection at all?
“We’re looking for incremental improvements and longer-acting drugs, trying to lengthen the time between injections for wet AMD patients,” said David Boyer, MD, a retina specialist in Los Angeles.
Two Drugs May Be Better Than One
One combination treatment, sozinibercept, targets VEGF-C and D. The therapy is in two phase 3 trials: One in combination with aflibercept 2 mg (Eylea), which targets VEGF-A and B along with placental growth factor, and the other in combination with ranibizumab, which targets VEGF-A only. Data from one of those trials are expected this year, Dr. Boyer said.
A phase 2 trial last year reported that patients on combination sozinibercept-ranibizumab had significantly better visual acuity improvement than patients on ranibizumab only. The phase 3 trials ShORe with ranibizumab and COAST with aflibercept are evaluating improvements in visual acuity and retinal anatomy.
Two other combination therapies are in phase 2 trials, both with aflibercept: UBX1325 or foselutoclax, a small-molecule inhibitor of B-cell lymphoma extra-large, and umedaptanib pegol, an anti-fibroblast growth factor-2 aptamer. In the foselutoclax-aflibercept trial, 40% of patients didn’t need a supplemental anti-VEGF injection through 48 weeks, and 64% went treatment-free for more than 24 weeks.
Phase 2 trials of intravitreal umedaptanib pegol-aflibercept combination therapy in nAMD last year showed no superiority in vision and anatomical improvements over aflibercept alone but did find the combination halted disease progression, with “striking improvement” in previously untreated patients.
Novel Drug Delivery Systems
A host of novel drug delivery systems that could stretch out intervals between injections are in human trials. In 2021, the FDA approved one such system, the refillable port delivery system (PDS) implant with ranibizumab (Susvimo). PDS is a small cylinder implanted into the eye and filled with 100 mg/mL of ranibizumab, to be released for 6 months or so, then refilled in the physician’s office when it’s empty.
But new implants of PDS were halted in 2022 after the manufacturer, Genentech, received reports the device leaked. Genentech said it has fixed those problems and confirmed the device should again become available for implants this year.
The most advanced novel drug delivery system in clinical trials is EYP-1901, a depot that contains the tyrosine kinase inhibitor (TKI) vorolanib. The depot is inserted under the ocular surface, where it biodegrades over 6 months as it releases the drug. A phase 3 trial is due to start enrollment at midyear.
An intravitreal implant with the TKI axitinib (Axpaxli) is in a phase 3 trial in nAMD and is due to start a phase 3 trial in diabetic retinopathy this year. At least four other implants, some of which biodegrade as they release the active ingredient, are in phase 1 or 2 trials.
TKIs themselves are a drug class worth watching in retina, said Jennifer I. Lim, MD, director of the retina service at the University of Illinois Chicago and president of the Retina Society.
“With TKIs, which activate intracellularly, in combination with anti-VEGFs will result in enhanced durability and possibly more efficacy for AMD,” Dr. Lim said. “TKIs in the phase 2 studies showed a marked reduction in the need for anti-VEGF injections in previously difficult-to-treat, high-need patient.”
Potential for Orals and Topicals
Topical eye drops are commonly used for anti-glaucoma drugs and antibiotics and corticosteroids for eye infections and inflammation, but using them for retinal disease has been a challenge. By the time the drug reaches the back of the eye, it has lost much of its pharmacokinetic activity. Three drops are in clinical trials for diabetic eye disease, with one, OCS-01, a preservative-free formulation of the corticosteroid dexamethasone, scheduled this year to enter a phase 3 trial.
At least four oral tablets are in early-stage human trials for diabetic eye disease. Four others are in clinical trials to treat geographic atrophy or early-stage dry AMD. They include tinlarebant, which is in phase 3 trials for geographic atrophy and Stargardt disease, an inherited retinal disorder.
Two other oral tablets are in human trials for inherited retinal disease. Like tinlarebant, emixustat has been in a phase 3 trial for Stargardt disease but showed no clinically significant improvement in macular atrophy. An early readout of an ongoing phase 2 trial of glideuretinol, a modified form of vitamin A, demonstrated slowed growth of macular atrophy in Stargardt.
These new and emerging treatments may potentially enable retina specialists to manage a rapidly growing aging population more efficiently, Dr. Sanders said.
“We have to figure out, on one hand, how do we catch the disease earlier? Like in other fields of medicine, the earlier you treat someone, the better,” Dr. Sanders said. “And also, how do we efficiently see these patients earlier to get therapy? Using implants or more durable drugs may be able to help us to treat more people more efficiently.”
Dr. Lim disclosed financial relationships with AbbVie/Allergan, Adverum Biotechnologies, Alimera Sciences, Bausch + Lomb, Chengdu Kanghong Biotechnology, Eyepoint Pharmaceuticals, Genentech/ Roche, Graybug Vision, Iveric Bio, Janssen Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, RegenxBio, Santen, SparingVision, Stealth BioTherapeutics, Unity Biotechnology, and Viridian.
Dr. Boyer disclosed financial relationships with 4D Molecular Therapeutics, AbbVie/Allergan, Adverum Biotechnologies, Aldeyra Therapeutics, Alimera Sciences, Alkahest, Allegro, Amgen, Annexon Biosciences, Apellis Pharmaceuticals, AsclepiX Therapeutics, Aviceda Therapeutics, Bausch + Lomb, Bayer, Belite Bio, Clearside Biomedical, Eyepoint Pharmaceuticals, Genentech/ Roche, Graybug Vision, Iveric Bio, Janssen Pharmaceuticals, Nano scope Therapeutics, Novartis, Ocugen, Oculist, Ocuphire Pharma, Opthea, Pfizer, Regeneron Pharmaceuticals, RegenxBio, Sanofi, Stilbite Zhuhai, Stealth BioTherapeutics, Thea Laboratories, and Unity Biotechnology. Dr. Sanders had no relevant disclosures.
A version of this article appeared on Medscape.com.
The burdens that monthly or every-other-month injections in the eye impose on patients with retinal diseases are well-known to be barriers to care for many people with these conditions. Making treatment less onerous has driven research into new treatments since the US Food and Drug Administration (FDA) approved ranibizumab (Lucentis) in 2006 as the first anti–vascular endothelial growth factor (VEGF) for the treatment of age-related macular degeneration (AMD) and other retinal diseases.
Those Several of those investigational therapies are poised to hit meaningful milestones in 2024.
Regular Eye Injections: How We Got Here
Ranibizumab originally received approval as a monthly injection. Since then, protocols have evolved to space those injections out to every other month in some, but not all, patients.
New drugs have emerged that require less frequent injections. In 2022, the anti-VEGF and angiopoietin-2 inhibitor faricimab (Vabysmo) was approved for dosing up to every 4 months. Last year, the FDA approved a high-dose formulation of the anti-VEGF treatment aflibercept 8 mg (Eylea HD) to be given every 2-4 months, as well.
But even these treatments require patients going to the office at least three or four times a year for injections, Reginald Sanders, MD, president of the American Society of Retina Specialist, Chicago, and a retina specialist in Washington, DC, told this news organization. “Now with injections, you have the anxiety of getting the injections, you have the inconvenience of coming in on a regular basis to get the injections, and you have mild discomfort — but you don’t go blind,” Dr. Sanders said.
Studies have shown patients with AMD or diabetic macular edema are better off getting more frequent injections, but still drug developers are seeking the holy grail of fewer injections. “How do we make these treatments last longer?” Dr. Sanders said. “Durability has become the catchword in our field. Instead of lasting a month or 2, can it last 3 months? Can it last 6 months? Or even a year? Can you get one injection and be done with it?”
Or, no injection at all?
“We’re looking for incremental improvements and longer-acting drugs, trying to lengthen the time between injections for wet AMD patients,” said David Boyer, MD, a retina specialist in Los Angeles.
Two Drugs May Be Better Than One
One combination treatment, sozinibercept, targets VEGF-C and D. The therapy is in two phase 3 trials: One in combination with aflibercept 2 mg (Eylea), which targets VEGF-A and B along with placental growth factor, and the other in combination with ranibizumab, which targets VEGF-A only. Data from one of those trials are expected this year, Dr. Boyer said.
A phase 2 trial last year reported that patients on combination sozinibercept-ranibizumab had significantly better visual acuity improvement than patients on ranibizumab only. The phase 3 trials ShORe with ranibizumab and COAST with aflibercept are evaluating improvements in visual acuity and retinal anatomy.
Two other combination therapies are in phase 2 trials, both with aflibercept: UBX1325 or foselutoclax, a small-molecule inhibitor of B-cell lymphoma extra-large, and umedaptanib pegol, an anti-fibroblast growth factor-2 aptamer. In the foselutoclax-aflibercept trial, 40% of patients didn’t need a supplemental anti-VEGF injection through 48 weeks, and 64% went treatment-free for more than 24 weeks.
Phase 2 trials of intravitreal umedaptanib pegol-aflibercept combination therapy in nAMD last year showed no superiority in vision and anatomical improvements over aflibercept alone but did find the combination halted disease progression, with “striking improvement” in previously untreated patients.
Novel Drug Delivery Systems
A host of novel drug delivery systems that could stretch out intervals between injections are in human trials. In 2021, the FDA approved one such system, the refillable port delivery system (PDS) implant with ranibizumab (Susvimo). PDS is a small cylinder implanted into the eye and filled with 100 mg/mL of ranibizumab, to be released for 6 months or so, then refilled in the physician’s office when it’s empty.
But new implants of PDS were halted in 2022 after the manufacturer, Genentech, received reports the device leaked. Genentech said it has fixed those problems and confirmed the device should again become available for implants this year.
The most advanced novel drug delivery system in clinical trials is EYP-1901, a depot that contains the tyrosine kinase inhibitor (TKI) vorolanib. The depot is inserted under the ocular surface, where it biodegrades over 6 months as it releases the drug. A phase 3 trial is due to start enrollment at midyear.
An intravitreal implant with the TKI axitinib (Axpaxli) is in a phase 3 trial in nAMD and is due to start a phase 3 trial in diabetic retinopathy this year. At least four other implants, some of which biodegrade as they release the active ingredient, are in phase 1 or 2 trials.
TKIs themselves are a drug class worth watching in retina, said Jennifer I. Lim, MD, director of the retina service at the University of Illinois Chicago and president of the Retina Society.
“With TKIs, which activate intracellularly, in combination with anti-VEGFs will result in enhanced durability and possibly more efficacy for AMD,” Dr. Lim said. “TKIs in the phase 2 studies showed a marked reduction in the need for anti-VEGF injections in previously difficult-to-treat, high-need patient.”
Potential for Orals and Topicals
Topical eye drops are commonly used for anti-glaucoma drugs and antibiotics and corticosteroids for eye infections and inflammation, but using them for retinal disease has been a challenge. By the time the drug reaches the back of the eye, it has lost much of its pharmacokinetic activity. Three drops are in clinical trials for diabetic eye disease, with one, OCS-01, a preservative-free formulation of the corticosteroid dexamethasone, scheduled this year to enter a phase 3 trial.
At least four oral tablets are in early-stage human trials for diabetic eye disease. Four others are in clinical trials to treat geographic atrophy or early-stage dry AMD. They include tinlarebant, which is in phase 3 trials for geographic atrophy and Stargardt disease, an inherited retinal disorder.
Two other oral tablets are in human trials for inherited retinal disease. Like tinlarebant, emixustat has been in a phase 3 trial for Stargardt disease but showed no clinically significant improvement in macular atrophy. An early readout of an ongoing phase 2 trial of glideuretinol, a modified form of vitamin A, demonstrated slowed growth of macular atrophy in Stargardt.
These new and emerging treatments may potentially enable retina specialists to manage a rapidly growing aging population more efficiently, Dr. Sanders said.
“We have to figure out, on one hand, how do we catch the disease earlier? Like in other fields of medicine, the earlier you treat someone, the better,” Dr. Sanders said. “And also, how do we efficiently see these patients earlier to get therapy? Using implants or more durable drugs may be able to help us to treat more people more efficiently.”
Dr. Lim disclosed financial relationships with AbbVie/Allergan, Adverum Biotechnologies, Alimera Sciences, Bausch + Lomb, Chengdu Kanghong Biotechnology, Eyepoint Pharmaceuticals, Genentech/ Roche, Graybug Vision, Iveric Bio, Janssen Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, RegenxBio, Santen, SparingVision, Stealth BioTherapeutics, Unity Biotechnology, and Viridian.
Dr. Boyer disclosed financial relationships with 4D Molecular Therapeutics, AbbVie/Allergan, Adverum Biotechnologies, Aldeyra Therapeutics, Alimera Sciences, Alkahest, Allegro, Amgen, Annexon Biosciences, Apellis Pharmaceuticals, AsclepiX Therapeutics, Aviceda Therapeutics, Bausch + Lomb, Bayer, Belite Bio, Clearside Biomedical, Eyepoint Pharmaceuticals, Genentech/ Roche, Graybug Vision, Iveric Bio, Janssen Pharmaceuticals, Nano scope Therapeutics, Novartis, Ocugen, Oculist, Ocuphire Pharma, Opthea, Pfizer, Regeneron Pharmaceuticals, RegenxBio, Sanofi, Stilbite Zhuhai, Stealth BioTherapeutics, Thea Laboratories, and Unity Biotechnology. Dr. Sanders had no relevant disclosures.
A version of this article appeared on Medscape.com.
The burdens that monthly or every-other-month injections in the eye impose on patients with retinal diseases are well-known to be barriers to care for many people with these conditions. Making treatment less onerous has driven research into new treatments since the US Food and Drug Administration (FDA) approved ranibizumab (Lucentis) in 2006 as the first anti–vascular endothelial growth factor (VEGF) for the treatment of age-related macular degeneration (AMD) and other retinal diseases.
Those Several of those investigational therapies are poised to hit meaningful milestones in 2024.
Regular Eye Injections: How We Got Here
Ranibizumab originally received approval as a monthly injection. Since then, protocols have evolved to space those injections out to every other month in some, but not all, patients.
New drugs have emerged that require less frequent injections. In 2022, the anti-VEGF and angiopoietin-2 inhibitor faricimab (Vabysmo) was approved for dosing up to every 4 months. Last year, the FDA approved a high-dose formulation of the anti-VEGF treatment aflibercept 8 mg (Eylea HD) to be given every 2-4 months, as well.
But even these treatments require patients going to the office at least three or four times a year for injections, Reginald Sanders, MD, president of the American Society of Retina Specialist, Chicago, and a retina specialist in Washington, DC, told this news organization. “Now with injections, you have the anxiety of getting the injections, you have the inconvenience of coming in on a regular basis to get the injections, and you have mild discomfort — but you don’t go blind,” Dr. Sanders said.
Studies have shown patients with AMD or diabetic macular edema are better off getting more frequent injections, but still drug developers are seeking the holy grail of fewer injections. “How do we make these treatments last longer?” Dr. Sanders said. “Durability has become the catchword in our field. Instead of lasting a month or 2, can it last 3 months? Can it last 6 months? Or even a year? Can you get one injection and be done with it?”
Or, no injection at all?
“We’re looking for incremental improvements and longer-acting drugs, trying to lengthen the time between injections for wet AMD patients,” said David Boyer, MD, a retina specialist in Los Angeles.
Two Drugs May Be Better Than One
One combination treatment, sozinibercept, targets VEGF-C and D. The therapy is in two phase 3 trials: One in combination with aflibercept 2 mg (Eylea), which targets VEGF-A and B along with placental growth factor, and the other in combination with ranibizumab, which targets VEGF-A only. Data from one of those trials are expected this year, Dr. Boyer said.
A phase 2 trial last year reported that patients on combination sozinibercept-ranibizumab had significantly better visual acuity improvement than patients on ranibizumab only. The phase 3 trials ShORe with ranibizumab and COAST with aflibercept are evaluating improvements in visual acuity and retinal anatomy.
Two other combination therapies are in phase 2 trials, both with aflibercept: UBX1325 or foselutoclax, a small-molecule inhibitor of B-cell lymphoma extra-large, and umedaptanib pegol, an anti-fibroblast growth factor-2 aptamer. In the foselutoclax-aflibercept trial, 40% of patients didn’t need a supplemental anti-VEGF injection through 48 weeks, and 64% went treatment-free for more than 24 weeks.
Phase 2 trials of intravitreal umedaptanib pegol-aflibercept combination therapy in nAMD last year showed no superiority in vision and anatomical improvements over aflibercept alone but did find the combination halted disease progression, with “striking improvement” in previously untreated patients.
Novel Drug Delivery Systems
A host of novel drug delivery systems that could stretch out intervals between injections are in human trials. In 2021, the FDA approved one such system, the refillable port delivery system (PDS) implant with ranibizumab (Susvimo). PDS is a small cylinder implanted into the eye and filled with 100 mg/mL of ranibizumab, to be released for 6 months or so, then refilled in the physician’s office when it’s empty.
But new implants of PDS were halted in 2022 after the manufacturer, Genentech, received reports the device leaked. Genentech said it has fixed those problems and confirmed the device should again become available for implants this year.
The most advanced novel drug delivery system in clinical trials is EYP-1901, a depot that contains the tyrosine kinase inhibitor (TKI) vorolanib. The depot is inserted under the ocular surface, where it biodegrades over 6 months as it releases the drug. A phase 3 trial is due to start enrollment at midyear.
An intravitreal implant with the TKI axitinib (Axpaxli) is in a phase 3 trial in nAMD and is due to start a phase 3 trial in diabetic retinopathy this year. At least four other implants, some of which biodegrade as they release the active ingredient, are in phase 1 or 2 trials.
TKIs themselves are a drug class worth watching in retina, said Jennifer I. Lim, MD, director of the retina service at the University of Illinois Chicago and president of the Retina Society.
“With TKIs, which activate intracellularly, in combination with anti-VEGFs will result in enhanced durability and possibly more efficacy for AMD,” Dr. Lim said. “TKIs in the phase 2 studies showed a marked reduction in the need for anti-VEGF injections in previously difficult-to-treat, high-need patient.”
Potential for Orals and Topicals
Topical eye drops are commonly used for anti-glaucoma drugs and antibiotics and corticosteroids for eye infections and inflammation, but using them for retinal disease has been a challenge. By the time the drug reaches the back of the eye, it has lost much of its pharmacokinetic activity. Three drops are in clinical trials for diabetic eye disease, with one, OCS-01, a preservative-free formulation of the corticosteroid dexamethasone, scheduled this year to enter a phase 3 trial.
At least four oral tablets are in early-stage human trials for diabetic eye disease. Four others are in clinical trials to treat geographic atrophy or early-stage dry AMD. They include tinlarebant, which is in phase 3 trials for geographic atrophy and Stargardt disease, an inherited retinal disorder.
Two other oral tablets are in human trials for inherited retinal disease. Like tinlarebant, emixustat has been in a phase 3 trial for Stargardt disease but showed no clinically significant improvement in macular atrophy. An early readout of an ongoing phase 2 trial of glideuretinol, a modified form of vitamin A, demonstrated slowed growth of macular atrophy in Stargardt.
These new and emerging treatments may potentially enable retina specialists to manage a rapidly growing aging population more efficiently, Dr. Sanders said.
“We have to figure out, on one hand, how do we catch the disease earlier? Like in other fields of medicine, the earlier you treat someone, the better,” Dr. Sanders said. “And also, how do we efficiently see these patients earlier to get therapy? Using implants or more durable drugs may be able to help us to treat more people more efficiently.”
Dr. Lim disclosed financial relationships with AbbVie/Allergan, Adverum Biotechnologies, Alimera Sciences, Bausch + Lomb, Chengdu Kanghong Biotechnology, Eyepoint Pharmaceuticals, Genentech/ Roche, Graybug Vision, Iveric Bio, Janssen Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, RegenxBio, Santen, SparingVision, Stealth BioTherapeutics, Unity Biotechnology, and Viridian.
Dr. Boyer disclosed financial relationships with 4D Molecular Therapeutics, AbbVie/Allergan, Adverum Biotechnologies, Aldeyra Therapeutics, Alimera Sciences, Alkahest, Allegro, Amgen, Annexon Biosciences, Apellis Pharmaceuticals, AsclepiX Therapeutics, Aviceda Therapeutics, Bausch + Lomb, Bayer, Belite Bio, Clearside Biomedical, Eyepoint Pharmaceuticals, Genentech/ Roche, Graybug Vision, Iveric Bio, Janssen Pharmaceuticals, Nano scope Therapeutics, Novartis, Ocugen, Oculist, Ocuphire Pharma, Opthea, Pfizer, Regeneron Pharmaceuticals, RegenxBio, Sanofi, Stilbite Zhuhai, Stealth BioTherapeutics, Thea Laboratories, and Unity Biotechnology. Dr. Sanders had no relevant disclosures.
A version of this article appeared on Medscape.com.
<!--$RCSfile: InCopy_agile.xsl,v $ $Revision: 1.35 $-->
<!--$RCSfile: drupal.xsl,v $ $Revision: 1.7 $-->
<root generator="drupal.xsl" gversion="1.7"> <header> <fileName>167122</fileName> <TBEID>0C04ECD1.SIG</TBEID> <TBUniqueIdentifier>MD_0C04ECD1</TBUniqueIdentifier> <newsOrJournal>News</newsOrJournal> <publisherName>Frontline Medical Communications</publisherName> <storyname/> <articleType>2</articleType> <TBLocation>QC Done-All Pubs</TBLocation> <QCDate>20240229T151009</QCDate> <firstPublished>20240229T153050</firstPublished> <LastPublished>20240229T153050</LastPublished> <pubStatus qcode="stat:"/> <embargoDate/> <killDate/> <CMSDate>20240229T153050</CMSDate> <articleSource/> <facebookInfo/> <meetingNumber/> <byline>R. M. Kirkner</byline> <bylineText>RICHARD MARK KIRKNER</bylineText> <bylineFull>RICHARD MARK KIRKNER</bylineFull> <bylineTitleText/> <USOrGlobal/> <wireDocType/> <newsDocType/> <journalDocType/> <linkLabel/> <pageRange/> <citation/> <quizID/> <indexIssueDate/> <itemClass qcode="ninat:text"/> <provider qcode="provider:imng"> <name>IMNG Medical Media</name> <rightsInfo> <copyrightHolder> <name>Frontline Medical News</name> </copyrightHolder> <copyrightNotice>Copyright (c) 2015 Frontline Medical News, a Frontline Medical Communications Inc. company. All rights reserved. This material may not be published, broadcast, copied, or otherwise reproduced or distributed without the prior written permission of Frontline Medical Communications Inc.</copyrightNotice> </rightsInfo> </provider> <abstract/> <metaDescription>new treatments include combination therapies, novel drug delivery systems, and a host of oral and topical medications to boost gains in visual acuity and extend</metaDescription> <articlePDF/> <teaserImage/> <teaser>Combo treatments or new drug delivery methods may offer patients an alternative or prolonged intervals between injections.</teaser> <title>Will 2024 Be Easier on the Eyes?</title> <deck/> <disclaimer/> <AuthorList/> <articleURL/> <doi/> <pubMedID/> <publishXMLStatus/> <publishXMLVersion>1</publishXMLVersion> <useEISSN>0</useEISSN> <urgency/> <pubPubdateYear/> <pubPubdateMonth/> <pubPubdateDay/> <pubVolume/> <pubNumber/> <wireChannels/> <primaryCMSID/> <CMSIDs/> <keywords/> <seeAlsos/> <publications_g> <publicationData> <publicationCode>fp</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> <publicationData> <publicationCode>im</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> </publications_g> <publications> <term>15</term> <term canonical="true">21</term> </publications> <sections> <term canonical="true">39313</term> </sections> <topics> <term canonical="true">27442</term> </topics> <links/> </header> <itemSet> <newsItem> <itemMeta> <itemRole>Main</itemRole> <itemClass>text</itemClass> <title>Will 2024 Be Easier on the Eyes?</title> <deck/> </itemMeta> <itemContent> <p>The burdens that monthly or every-other-month injections in the eye impose on patients with retinal diseases are well-known to be barriers to care for many people with these conditions. Making treatment less onerous has driven research into new treatments since the <span class="Hyperlink"><a href="https://www.drugs.com/newdrugs/fda-approves-lucentis-ranibizumab-wet-age-related-macular-degeneration-327.html">US Food and Drug Administration (FDA) approved</a></span> ranibizumab (Lucentis) in 2006 as the first anti–vascular endothelial growth factor (VEGF) for the treatment of age-related macular degeneration (AMD) and other retinal diseases.</p> <p>Those <span class="tag metaDescription">new treatments include combination therapies, novel drug delivery systems, and a host of oral and topical medications to boost gains in visual acuity and extend the intervals between injections or avoid the injections altogether.</span> Several of those investigational therapies are poised to hit meaningful milestones in 2024.<br/><br/></p> <h2>Regular Eye Injections: How We Got Here</h2> <p>Ranibizumab originally received approval as a monthly injection. Since then, protocols have evolved to space those injections out to every other month in some, but not all, patients.<br/><br/>New drugs have emerged that require less frequent injections. In 2022, the anti-VEGF and angiopoietin-2 inhibitor <span class="Hyperlink"><a href="https://www.gene.com/media/press-releases/14943/2022-01-28/fda-approves-genentechs-vabysmo-the-firs">faricimab</a></span> (Vabysmo) was approved for dosing up to every 4 months. Last year, the FDA approved a high-dose formulation of the anti-VEGF treatment <span class="Hyperlink"><a href="https://investor.regeneron.com/news-releases/news-release-details/eylea-hd-aflibercept-injection-8-mg-approved-fda-treatment-wet">aflibercept</a></span> 8 mg (Eylea HD) to be given every 2-4 months, as well.<br/><br/>But even these treatments require patients going to the office at least three or four times a year for injections, Reginald Sanders, MD, president of the American Society of Retina Specialist, Chicago, and a retina specialist in Washington, DC, told this news organization. “Now with injections, you have the anxiety of getting the injections, you have the inconvenience of coming in on a regular basis to get the injections, and you have mild discomfort — but you don’t go blind,” Dr. Sanders said.<br/><br/>Studies have shown patients with <span class="Hyperlink"><a href="https://www.sciencedirect.com/science/article/pii/S2468653019302805?via%3Dihub">AMD</a></span> or <span class="Hyperlink"><a href="https://bjo.bmj.com/content/105/2/216.long">diabetic macular edema</a></span> are better off getting more frequent injections, but still drug developers are seeking the holy grail of fewer injections. “How do we make these treatments last longer?” Dr. Sanders said. “Durability has become the catchword in our field. Instead of lasting a month or 2, can it last 3 months? Can it last 6 months? Or even a year? Can you get one injection and be done with it?”<br/><br/>Or, no injection at all?<br/><br/>“We’re looking for incremental improvements and longer-acting drugs, trying to lengthen the time between injections for wet AMD patients,” said David Boyer, MD, a retina specialist in Los Angeles.<br/><br/></p> <h2>Two Drugs May Be Better Than One</h2> <p>One combination treatment, sozinibercept, targets VEGF-C and D. The therapy is in <span class="Hyperlink">two phase 3 trials</span>: One in combination with aflibercept 2 mg (Eylea), which targets VEGF-A and B along with placental growth factor, and the other in combination with ranibizumab, which targets VEGF-A only. Data from one of those trials are expected this year, Dr. Boyer said.<br/><br/>A <span class="Hyperlink"><a href="https://pubmed.ncbi.nlm.nih.gov/36754174/">phase 2 trial last year</a></span> reported that patients on combination sozinibercept-ranibizumab had significantly better visual acuity improvement than patients on ranibizumab only. The phase 3 trials <span class="Hyperlink"><a href="https://clinicaltrials.gov/study/NCT04757610">ShORe with ranibizumab</a></span> and <span class="Hyperlink"><a href="https://clinicaltrials.gov/study/NCT04757636">COAST with aflibercept</a></span> are evaluating improvements in visual acuity and retinal anatomy.<br/><br/>Two other combination therapies are in phase 2 trials, both with aflibercept: <span class="Hyperlink"><a href="https://ir.unitybiotechnology.com/news-releases/news-release-details/unity-biotechnology-doses-first-patients-phase-2-aspire-study">UBX1325 or foselutoclax</a></span>, a small-molecule inhibitor of B-cell lymphoma extra-large, and <span class="Hyperlink"><a href="https://ssl4.eir-parts.net/doc/4591/ir_material3/219444/00.pdf">umedaptanib pegol</a></span>, an anti-fibroblast growth factor-2 aptamer. In the foselutoclax-aflibercept <span class="Hyperlink"><a href="https://ir.unitybiotechnology.com/news-releases/news-release-details/unity-biotechnology-announces-48-week-results-phase-2-envision">trial</a></span>, 40% of patients didn’t need a supplemental anti-VEGF injection through 48 weeks, and 64% went treatment-free for more than 24 weeks.<br/><br/><span class="Hyperlink"><a href="https://www.nature.com/articles/s41433-023-02848-7.pdf">Phase 2 trials</a></span> of intravitreal umedaptanib pegol-aflibercept combination therapy in nAMD last year showed no superiority in vision and anatomical improvements over aflibercept alone but did find the combination halted disease progression, with “striking improvement” in previously untreated patients.<br/><br/></p> <h2>Novel Drug Delivery Systems</h2> <p>A host of novel drug delivery systems that could stretch out intervals between injections are in human trials. In 2021, <span class="Hyperlink"><a href="https://www.gene.com/media/press-releases/14935/2021-10-22/fda-approves-genentechs-susvimo-a-first-">the FDA approved one such system</a></span>, the refillable port delivery system (PDS) implant with ranibizumab (Susvimo). PDS is a small cylinder implanted into the eye and filled with 100 mg/mL of ranibizumab, to be released for 6 months or so, then refilled in the physician’s office when it’s empty.<br/><br/>But new implants of PDS <span class="Hyperlink"><a href="https://www.gene.com/download/pdf/Susvimo_DHCP_Important_Prescribing_Information_2022-10-18.pdf">were halted in 2022</a></span> after the manufacturer, Genentech, received reports the device leaked. Genentech said it has fixed those problems and confirmed the device should again become available for implants this year.<br/><br/>The most advanced novel drug delivery system in clinical trials is <span class="Hyperlink"><a href="https://investors.eyepointpharma.com/news-releases/news-release-details/eyepoint-pharmaceuticals-announces-positive-topline-data-phase-2">EYP-1901</a></span>, a depot that contains the tyrosine kinase inhibitor (TKI) vorolanib. The depot is inserted under the ocular surface, where it biodegrades over 6 months as it releases the drug. A phase 3 trial is due to start enrollment at midyear.<br/><br/>An intravitreal implant with the <span class="Hyperlink"><a href="https://www.globenewswire.com/news-release/2024/2/13/2828143/0/en/Ocular-Therapeutix-Announces-First-Subjects-Screened-in-Phase-3-Pivotal-Clinical-Trial-of-AXPAXLI-in-Wet-AMD.html">TKI axitinib</a></span> (Axpaxli) is in a phase 3 trial in nAMD and is due to start a phase 3 trial in diabetic retinopathy this year. At least four other implants, some of which biodegrade as they release the active ingredient, are in phase 1 or 2 trials.<br/><br/>TKIs themselves are a drug class worth watching in retina, said Jennifer I. Lim, MD, director of the retina service at the University of Illinois Chicago and president of the Retina Society.<br/><br/>“With TKIs, which activate intracellularly, in combination with anti-VEGFs will result in enhanced durability and possibly more efficacy for AMD,” Dr. Lim said. “TKIs in the phase 2 studies showed a marked reduction in the need for anti-VEGF injections in previously difficult-to-treat, high-need patient.”<br/><br/></p> <h2>Potential for Orals and Topicals</h2> <p>Topical eye drops are commonly used for anti-glaucoma drugs and antibiotics and corticosteroids for eye infections and inflammation, but using them for retinal disease has been a challenge. By the time the drug reaches the back of the eye, it has lost much of its pharmacokinetic activity. Three drops are in clinical trials for diabetic eye disease, with one, <span class="Hyperlink"><a href="https://investors.oculis.com/news-releases/news-release-details/oculis-announces-first-patient-first-visit-phase-3-diamond-1">OCS-01, a preservative-free formulation</a></span> of the corticosteroid dexamethasone, scheduled this year to enter a phase 3 trial.<br/><br/>At least four oral tablets are in early-stage human trials for diabetic eye disease. Four others are in clinical trials to treat geographic atrophy or early-stage dry AMD. They <span class="Hyperlink"><a href="https://investors.belitebio.com/news-releases/news-release-details/belite-bio-receives-approval-initiate-tinlarebant-phase-3">include tinlarebant</a></span>, which is in phase 3 trials for geographic atrophy and Stargardt disease, an inherited retinal disorder.<br/><br/>Two other oral tablets are in human trials for inherited retinal disease. Like tinlarebant, <span class="Hyperlink"><a href="https://clinicaltrials.gov/study/NCT03772665?cond=Stargardt%20Disease&intr=Emixustat&rank=1&a=13">emixustat</a></span> has been in a phase 3 trial for Stargardt disease but showed no clinically significant improvement in macular atrophy. An early readout of an ongoing phase 2 trial of <span class="Hyperlink"><a href="https://www.medscape.com/viewarticle/998609?_gl=1*18zdzms*_ga*NjkzMDg5MzY2LjE3MDgwOTcyMDY.*_ga_FZV5XMCPSP*MTcwODI4OTU3NS41LjEuMTcwODI4OTYwMi4wLjAuMA..*_fplc*UnZXaFI1SnAzaHQ1TyUyQnVkZ3dlRyUyRjUlMkJRMlpYUlh3NkIlMkIxTiUyRmZFdWV5dHpQcnF0YU9odFNFNVF0ak9YWCUyRmlVZ3NuYWVucXg0SWVScVFnUnNTaDBYenE4RXh5bThjSGduRFByRGNBJTJGY2ZWSElHaE50S2tVRDVrWmZHbzBncmclM0QlM0Q.">glideuretinol</a></span>, a modified form of vitamin A, demonstrated slowed growth of macular atrophy in Stargardt.<br/><br/>These new and emerging treatments may potentially enable retina specialists to manage a rapidly growing aging population more efficiently, Dr. Sanders said.<br/><br/>“We have to figure out, on one hand, how do we catch the disease earlier? Like in other fields of medicine, the earlier you treat someone, the better,” Dr. Sanders said. “And also, how do we efficiently see these patients earlier to get therapy? Using implants or more durable drugs may be able to help us to treat more people more efficiently.”<br/><br/>Dr. Lim disclosed financial relationships with AbbVie/Allergan, Adverum Biotechnologies, Alimera Sciences, Bausch + Lomb, Chengdu Kanghong Biotechnology, Eyepoint Pharmaceuticals, Genentech/ Roche, Graybug Vision, Iveric Bio, Janssen Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, RegenxBio, Santen, SparingVision, Stealth BioTherapeutics, Unity Biotechnology, and Viridian.<br/><br/>Dr. Boyer disclosed financial relationships with 4D Molecular Therapeutics, AbbVie/Allergan, Adverum Biotechnologies, Aldeyra Therapeutics, Alimera Sciences, Alkahest, Allegro, Amgen, Annexon Biosciences, Apellis Pharmaceuticals, AsclepiX Therapeutics, Aviceda Therapeutics, Bausch + Lomb, Bayer, Belite Bio, Clearside Biomedical, Eyepoint Pharmaceuticals, Genentech/ Roche, Graybug Vision, Iveric Bio, Janssen Pharmaceuticals, Nano scope Therapeutics, Novartis, Ocugen, Oculist, Ocuphire Pharma, Opthea, Pfizer, Regeneron Pharmaceuticals, RegenxBio, Sanofi, Stilbite Zhuhai, Stealth BioTherapeutics, Thea Laboratories, and Unity Biotechnology. Dr. Sanders had no relevant disclosures.<br/><br/></p> <p> <em>A version of this article appeared on <span class="Hyperlink"><a href="https://www.medscape.com/viewarticle/will-2024-be-easier-eyes-2024a10003yn">Medscape.com</a></span>.</em> </p> </itemContent> </newsItem> <newsItem> <itemMeta> <itemRole>teaser</itemRole> <itemClass>text</itemClass> <title/> <deck/> </itemMeta> <itemContent> </itemContent> </newsItem> </itemSet></root>